KEY FINDINGS IN LATEST RESEARCH

August, 2017

Top Attributes Driving Asthma Access Decisions

Net pricing and outcomes data most drive health plan access decisions for branded asthma drugs; clinical data most drive medical group choices.

August, 2017

Commercial plans prioritize cost reduction

Biopharmaceutical companies can leverage the importance commercial plans place on clinical goals by offering compelling, clinically differentiating value propositions for their products in order to direct plans to shift their focus beyond unit product costs to total disease/care management

August, 2017

Payers Will Decrease Reliance on PBMs If They Fail To Improve their Services by Developing Specific Capabilities

The majority of health plans and employers anticipate accessing important services and capabilities through internal development or external contracting if PBM offerings remain unsatisfactory.

August, 2017

Prevalence of Base-Price Discount Contracts Diminishes as IDNs Increase Experimentation with Different Contracts

IDNs favor outcomes-based contracts for categories in which outcomes can be objectively measured. While outcomes-based contracts are still uncommon, IDNs most prefer them for antibiotics, COPD, hepatitis C, and multiple sclerosis agents.

August, 2017

Pricing, Net Costs Most Important Attributes in Plan Access Decisions

Pricing and overall net costs are the most important attributes in health plan access decisions for psoriasis drugs; medical groups are more driven by safety and quality-of-life metrics.

Subscribe to RSS - blogs

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.